^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Macrophage modulator

12d
Caulerpin alleviates cyclophosphamide-induced ovarian toxicity by modulating macrophage-associated granulosa cell senescence during breast cancer chemotherapy. (PubMed, Int Immunopharmacol)
Furthermore, caulerpin or a p53 inhibitor (pifithrin-α) modulated CTX-induced M1 polarization in macrophages, thereby delaying GC senescence. These findings demonstrated that caulerpin contributes to alleviating CTX-induced ovarian toxicity by modulating M1 macrophage polarization through the p53/NF-κB signaling pathway, which promotes the senescence of GCs by inducing ROS production.Thus, caulerpin may be a potential therapeutic strategy for breast cancer patients.
Journal
|
IFNG (Interferon, gamma) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
cyclophosphamide
1m
Bromodomain containing 4 inhibition combats gastric precancerous lesions via modulating macrophage polarization. (PubMed, Tissue Cell)
Through in vivo and in vitro experiments, BRD4 upregulation was found to already occur during GPL, affecting macrophage polarization and epithelial cell cancerization. This finding provides an experimental basis for strategies targeting BRD4 inhibition at this critical stage.
Journal
|
BRD4 (Bromodomain Containing 4)
2ms
Tumor-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signaling. (PubMed, iScience)
We show that stromal cell-mediated suppression of macrophage phagocytosis is mediated in part through PD-1 signaling. These data suggest that re-stratification of CRC by CMS may reveal patient subsets with microsatellite stable tumors, particularly CMS4-like tumors, that may respond to immunotherapies.
Journal • PD(L)-1 Biomarker • IO biomarker • Stroma
|
PD-L1 (Programmed death ligand 1) • CD47 (CD47 Molecule)
|
PD-L1 expression
3ms
New trial
|
TREM2 (Triggering Receptor Expressed On Myeloid Cells 2)
3ms
Modulating macrophage-mediated programmed cell removal: An attractive strategy for cancer therapy. (PubMed, Biochim Biophys Acta Rev Cancer)
In addition, we highlight the molecular regulatory mechanisms that affect immune system function by exciting or suppressing PrCR. Finally, we review the research advances in tumour therapy by activating PrCR and discuss the challenges and potential solutions to smooth the way for tumour treatment strategies that target PrCR.
Review • Journal
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD24 (CD24 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • VCAM1 (Vascular Cell Adhesion Molecule 1) • LILRB1 (Leukocyte Immunoglobulin Like Receptor B1) • SIRPA (Signal Regulatory Protein Alpha) • SLAMF7 (SLAM Family Member 7)
3ms
Trial completion • Metastases
|
ALK (Anaplastic lymphoma kinase)
|
Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)
4ms
Macrophages modulate mesenchymal stem cell function via tumor necrosis factor alpha in tooth extraction model. (PubMed, JBMR Plus)
A macrophage-depleted tooth extraction model was generated in 5-wk-old female C57BL/6J mice using clodronate liposome (12.5 mg/kg/mouse, intraperitoneally) or saline injection (control) before maxillary first molar extraction...Temporal reduction followed by apparent recovery of TNF-α-producing M1 macrophages and MSCs after temporal macrophage depletion suggests that TNF-α activated MSCs during TES healing. In vitro mimicking the effect of TNF-α on MSCs indicated that there are 15 candidate MSC genes for regulation of immunomodulatory capacity.
Journal
|
PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • MRC1 (Mannose Receptor C-Type 1) • CD80 (CD80 Molecule)
|
clodronate disodium
4ms
NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. (PubMed, J Immunother Cancer)
NNMT+ CAFs were significantly associated with non-response to PD-L1 blockade immunotherapy in patients with UBC. Elevated NNMT, specifically in CAFs, upregulates SAA expression and enhances the recruitment and differentiation of macrophages in the tumor microenvironment, thereby directly or indirectly promoting tumor progression and conferring resistance to immunotherapies in bladder cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
NNMT (Nicotinamide N-Methyltransferase)
4ms
Irisin alleviates CFA-induced inflammatory pain by modulating macrophage polarization and spinal glial cell activation. (PubMed, Biomed Pharmacother)
Irisin alleviated inflammatory pain by modulating local tissue inflammation and peripheral and central neuroinflammation and reducing glial cell activation and M2 macrophage polarization by modulating the TLR4-MyD88-IRF5 signaling pathway. Accordingly, irisin is a promising candidate for treating inflammatory pain in various diseases.
Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta) • GFAP (Glial Fibrillary Acidic Protein) • IRF5 (Interferon Regulatory Factor 5)
4ms
PIM1/NF-κB/CCL2 blockade enhances anti-PD-1 therapy response by modulating macrophage infiltration and polarization in tumor microenvironment of NSCLC. (PubMed, Oncogene)
Furthermore, Dual blockade of Pim1 and PD-1 collaboratively suppressed tumor growth, repolarized macrophages, and boosted the efficacy of anti-PD-1 antibody. Collectively, our findings elucidate the pivotal role of PIM1 in orchestrating TAMs within the TME of NSCLC and highlight the potential of PIM1 inhibition as a strategy for enhancing the efficacy of cancer immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PIM1 (Pim-1 Proto-Oncogene) • CCL2 (Chemokine (C-C motif) ligand 2)
4ms
The role of MNK1-mTORC1 pathway in modulating macrophage responses to Vibrio vulnificus infection. (PubMed, Microbiol Spectr)
MNK1 also impairs phagocytosis, bacterial clearance, and phagosome acidification in Vv-infected cells through the MNK1-mammalian target of rapamycin complex 1 (mTORC1) signaling pathway. The findings highlight the importance of the MNK1-mTORC1 pathway in modulating macrophage responses to Vv infection.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
6ms
Non-invasive Physical Plasma Modulates Macrophage Polarization: A Potential Strategy for Tumor Microenvironment Remodeling. (PubMed, Anticancer Res)
NIPP is a safe and robust oxidative stress inducer and showed potential in TAM regulation by promoting M1 macrophage polarization.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MRC1 (Mannose Receptor C-Type 1)
6ms
LYVE-1-expressing macrophages modulate the hyaluronan-containing extracellular matrix in the mammary stroma and contribute to mammary tumor growth. (PubMed, Cancer Res Commun)
Analysis of single cell RNA sequencing of macrophages isolated from these tumors reveals that depletion of LYVE-1+ macrophages in tumors drives a shift in the majority of the remaining macrophages towards a pro-inflammatory phenotype, as well as an increase in CD8+ T cell infiltration. Together, these findings indicate that LYVE-1+ macrophages represent a tumor-promoting anti-inflammatory subset of macrophages that contributes to hyaluronan remodeling in the tumor microenvironment.
Journal • Stroma
|
CD8 (cluster of differentiation 8) • LYVE1 (Lymphatic vessel endothelial hyaluronan receptor 1)
7ms
Exosomal NAT10 from esophageal squamous cell carcinoma cells modulates macrophage lipid metabolism and polarization through ac4C modification of FASN. (PubMed, Transl Oncol)
In vivo animal studies demonstrated that targeting NAT10 could enhance the therapeutic effect of PD-1 on ESCC by mediating macrophage reprogramming. Our findings offer novel insights into improving ESCC treatment through NAT10 targeting.
Journal • PD(L)-1 Biomarker • IO biomarker
|
FASN (Fatty acid synthase) • METTL3 (Methyltransferase Like 3)
7ms
Syringic acid attenuates acute lung injury by modulating macrophage polarization in LPS-induced mice. (PubMed, Phytomedicine)
SA has possessed a crucial anti-ALI role in LPS-induced mice. The mechanism was elucidated, suggesting that the inhibition of macrophage polarization to M1-type and the promotion of macrophage polarization to M2-type, as well as the inhibition of NF-κB pathway by SA may be the reasons for its anti-ALI. This finding provides important molecular evidence for the further application of SA in the clinical treatment of ALI.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • IL1B (Interleukin 1, beta) • NFKBIA (NFKB Inhibitor Alpha 2)
|
PTGS2 expression • IL6 expression
7ms
ALKBH5 modulates macrophages polarization in tumor microenvironment of ovarian cancer. (PubMed, J Ovarian Res)
ALKBH5 participated in regulating macrophage M2 polarization in ovarian cancer immune microenvironment.
Journal
|
ALKBH5 (AlkB Homolog 5, RNA Demethylase) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
7ms
Macrophage-Derived Nanosponges Adsorb Cytokines and Modulate Macrophage Polarization for Renal Cell Carcinoma Immunotherapy. (PubMed, Adv Healthc Mater)
In addition, these nanosponges exhibited undetectable biotoxicity, making them suitable for clinical applications. In summary, we provide a promising and facile strategy for immunomodulatory therapies, which are expected to be used in the treatment of tumors, autoimmune diseases, and inflammatory diseases.
Journal
|
CD8 (cluster of differentiation 8) • CSF1 (Colony stimulating factor 1) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1)
7ms
Taurine Inhibits Lung Metastasis in Triple-Negative Breast Cancer by Modulating Macrophage Polarization Through PTEN-PI3K/Akt/mTOR Pathway. (PubMed, J Immunother)
Our findings suggest that Tau inhibits the activation of the PI3K-Akt-mTOR signaling pathway by up-regulating PTEN, promotes the proportion of M1 macrophages in tumor-associated macrophage, and suppresses the invasion and metastasis of TNBC. This provides a potential therapeutic approach to influence cancer progression and metastasis.
Journal
|
PTEN (Phosphatase and tensin homolog) • IL4 (Interleukin 4)
|
PTEN expression
7ms
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
P1, N=5, Terminated, HiberCell, Inc. | N=45 --> 5 | Trial completion date: Apr 2027 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Mar 2024; sponsor decision
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
CDX-1140 • Imprime PGG (odetiglucan)
8ms
23-Hydroxybetulinic acid attenuates 5-fluorouracil resistance of colorectal cancer by modulating M2 macrophage polarization via STAT6 signaling. (PubMed, Cancer Immunol Immunother)
Furthermore, 23-HBA significantly diminished the proportion of M2 macrophages in the tumor tissues of colorectal cancer mice, simultaneously enhancing the anti-cancer efficacy of 5-FU. The findings presented in this study highlight the capacity of 23-HBA to inhibit M2 macrophage polarization, a process that contributes to reduced 5-FU resistance in colorectal cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • STAT6 (Signal transducer and activator of transcription 6) • ARG1 (Arginase 1) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1)
|
5-fluorouracil
8ms
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001. (PubMed, J Exp Clin Cancer Res)
RCT001, by inhibiting CXCR2 through its unique mechanism, effectively suppresses ccRCC cell proliferation, angiogenesis, and M2 macrophage polarization. This optimization potentiates the efficacy of immunotherapy and holds promise for significantly improving the survival prospects of metastatic ccRCC patients.
Journal
|
CD4 (CD4 Molecule) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
9ms
Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K/AKT pathway. (PubMed, Phytother Res)
It also reduced the expression of angiogenesis and cell proliferation markers in tumour tissues, decreased the quantity of M2 macrophages and their associated markers and pathway proteins. In conclusion, CuB impedes osteosarcoma progression by inhibiting M2 macrophage differentiation via the PI3K/AKT pathway, presenting the potential for therapeutic advancements in osteosarcoma treatment.
Journal
|
IL13 (Interleukin 13) • IL4 (Interleukin 4)
9ms
Deciphering the Dual Role of Heligmosomoides polygyrus Antigens in Macrophage Modulation and Breast Cancer Cell Growth. (PubMed, Vet Sci)
Our findings indicate that the antigens from H. polygyrus markedly alter macrophage behavior and increase the proliferation of breast cancer cells in a laboratory setting. This study contributes to a deeper understanding of the complex interactions between parasitic infections and cancer development, highlighting the need for further research in this area to develop potential new strategies for cancer treatment.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • ITGAM (Integrin, alpha M) • TLR4 (Toll Like Receptor 4)
9ms
New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression
10ms
Wuling capsule modulates macrophage polarization by inhibiting the TLR4-NF-κB signaling pathway to relieve liver fibrosis. (PubMed, Int Immunopharmacol)
This study demonstrated that WL modulated macrophage polarization against liver fibrosis mainly by inhibiting the activation of the TLR4-NF-κB signaling pathway.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TLR4 (Toll Like Receptor 4) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule)
|
IL6 expression
10ms
Atorvastatin ameliorated myocardial fibrosis in db/db mice by inhibiting oxidative stress and modulating macrophage polarization. (PubMed, World J Diabetes)
Administration of atorvastatin attenuates myocardial fibrosis in db/db mice, which may be associated with the antioxidative stress and anti-inflammatory effects of atorvastatin on diabetic myocardium through modulating macrophage polarization.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1)
10ms
Porcine Intestinal Mucosal Peptides Target Macrophage-Modulated Inflammation and Alleviate Intestinal Homeostasis in Dextrose Sodium Sulfate-Induced Colitis in Mice. (PubMed, Foods)
These findings suggest that PIMP may positively influence inflammatory responses and alleviate colitis. This study is the first to demonstrate the potential of PIMP as a functional food for the prevention and treatment of colitis.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • MPO (Myeloperoxidase)
|
IL6 expression
11ms
Potassium channel modulation in macrophages sensitizes dorsal root ganglion neurons after nerve injury. (PubMed, Glia)
Blocking protein trafficking in neurons reduced the effect of CM, suggesting that the hyperexcitable state resulted from changes in Na channel trafficking. These results suggest that DRG macrophages, primed by peripheral nerve injury, contribute to neuron-glia crosstalk, Na channel dysregulation and neuronal hyperexcitability implicated in the development of neuropathic pain.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • GFAP (Glial Fibrillary Acidic Protein)
11ms
RNA-based modulation of macrophage-mediated efferocytosis potentiates antitumor immunity in colorectal cancer. (PubMed, J Control Release)
siMerTK delivery combined with PD-1 blockade further produces enhanced antimetastatic efficacy with reactivated intratumoral immune milieu. Collectively, LNP-based siMerTK delivery combined with immune checkpoint therapy may present a feasible modality for metastatic colorectal cancer therapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
MERTK (MER Proto-Oncogene, Tyrosine Kinase)
|
MERTK expression
11ms
Bacille-Calmette-Guerin modulates human macrophage and dendritic cell response to SARS-CoV-2 S-glycoprotein. (PubMed, Infect Med (Beijing))
BCG-induced trained immunity may be an important tool for reducing susceptibility to SARS-CoV-2 infection and severity of COVID-19. Our findings help in the design of future BCG-based therapeutic approaches in the treatment of diseases caused by viral infections.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
1year
Irradiated Tumor Cells-Derived Exosomes Modulate Macrophage Polarization by Targeting SHP-2 Mediated Metabolic Reprogramming. (PubMed, Int J Radiat Oncol Biol Phys)
Our study demonstrates that exosomal miR-138-5p from irradiated tumor cells can modulate macrophage polarization by targeting SHP-2. And SHP-2 negatively regulates glycolysis and polarize macrophage to an M2 phenotype by SHP-2/PKM2(Tyr105) (Ser37)/β-catenin/LDHA/Glut-1 axis.
Journal • Tumor cell
|
LDHA (Lactate dehydrogenase A) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MIR138 (MicroRNA 138) • PKM (Pyruvate Kinase M1/2) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
SHP099
1year
Irradiated Tumor Cells-derived Exosomes Modulate Macrophage Polarization by Targeting SHP-2 Mediated Metabolic Reprogramming (ASTRO 2023)
Thus, the SHP099 (a SHP-2 inhibitor) can uptake and utilization of glucose by SHP-2/PKM2(Tyr105) (Ser37)/ß-catenin/LDHA/Glut-1 axis, suggesting that SHP099 plays positive roles on glycolysis and M1-polarized... Our study demonstrates that exosomal miR-138-5p from irradiated tumor cells can modulate macrophage polarization by targeting SHP-2. And SHP-2 negatively regulates glycolysis and polarize macrophage to an M2 phenotype by SHP-2/PKM2(Tyr105) (Ser37)/ß-catenin/LDHA/Glut-1 axis.
Tumor cell
|
LDHA (Lactate dehydrogenase A) • MIR138 (MicroRNA 138) • PKM (Pyruvate Kinase M1/2) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
SHP099
over1year
A Maintenance Therapy Study of Odetiglucan With a CD40 Agonist (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
P1, N=45, Recruiting, HiberCell, Inc. | N=30 --> 45 | Trial completion date: Mar 2026 --> Apr 2027 | Trial primary completion date: Mar 2025 --> Nov 2025
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
CDX-1140 • Imprime PGG (odetiglucan)
over1year
LncRNA MEG3 Inhibits Tumor Progression by Modulating Macrophage Phenotypic Polarization via miR-145-5p/DAB2 Axis in Hepatocellular Carcinoma. (PubMed, J Hepatocell Carcinoma)
Overexpressing MEG3 suppressed M2 polarization-induced HCC cell metastasis and angiogenesis by upregulating DAB2 and inhibited in vivo tumor growth. LncRNA MEG3 curbs HCC development by repressing M2 macrophage polarization via miR-145-5p/DAB2 axis.
Journal
|
IFNG (Interferon, gamma) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1) • DAB2 (DAB Adaptor Protein 2) • MEG3 (Maternally Expressed 3) • MIR145 (MicroRNA 145)
over1year
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) (clinicaltrials.gov)
P2, N=26, Completed, HiberCell, Inc. | Active, not recruiting --> Completed | N=50 --> 26 | Trial completion date: Jan 2027 --> Apr 2023 | Trial primary completion date: Jan 2025 --> Mar 2023
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • CD86 (CD86 Molecule)
|
PIK3CA mutation
|
Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)
over1year
miR-210 promotes hepatocellular carcinoma progression by modulating macrophage autophagy through PI3K/AKT/mTOR signaling. (PubMed, Biochem Biophys Res Commun)
miR-210 can promote autophagy of M2 macrophages via PI3K/AKT/mTOR signaling pathway. M2 macrophage-derived miR-210 promotes the malignant progression of HCC via autophagy, suggesting that macrophage autophagy may serve as a new therapeutic target for HCC, and targeting miR-210 may reset the effect of M2 macrophages on HCC.
Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • MIR210 (MicroRNA 210)
over1year
OSMR deficiency aggravates pressure overload-induced cardiac hypertrophy by modulating macrophages and OSM/LIFR/STAT3 signalling. (PubMed, J Transl Med)
OSMR deficiency aggravated pressure overload-induced cardiac hypertrophy by modulating macrophages and OSM/LIFR/STAT3 signalling, which provided evidence that OSMR might be an attractive target for treating pathological cardiac hypertrophy and heart failure.
Journal
|
IL6 (Interleukin 6) • LIFR (LIF Receptor Subunit Alpha) • OSMR (Oncostatin M Receptor)
over1year
Clinical • P1 data • Combination therapy • Metastases
|
CD40 (CD40 Molecule)
|
CDX-1140 • Imprime PGG (odetiglucan)
over1year
Dioscin modulates macrophages polarization and MDSCs differentiation to inhibit tumorigenesis of colitis-associated colorectal cancer. (PubMed, Int Immunopharmacol)
Based on the plasticity of MDSCs and its ability to differentiate into M1/M2 macrophages, we here found that Dioscin increased M1- and decreased M2-like phenotype during the process of MDSCs differentiation in vitro, suggesting Dioscin promoted MDSCs differentiate into M1 as well as inhibited its differentiation into M2 macrophages. Taken together, our study indicated that Dioscin had the inhibitory effect on the initial of tumorigenesis at early stage of CAC via the ant-inflammatory effect, which provided a natural active candidate for effective prevention of CAC.
Journal
|
IL4 (Interleukin 4)
over1year
Schwann cell-derived CXCL2 contributes to cancer pain by modulating macrophage infiltration in a mouse breast cancer model. (PubMed, Brain Behav Immun)
Mechanistically, we found that redox effector factor-1 (Ref-1) secreted by breast cancer cells activated hypoxia inducible factor-1α (HIF-1α) expression and inhibited reactive oxygen species (ROS) production in Schwann cells, ultimately inducing CXCL2 expression in Schwann cells. In brief, the present study expands new insights into cancer pain mechanisms from promising animal models to provide new strategies for the control of cancer pain.
Preclinical • Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
HIF1A expression